| Dr Dianne Sherill Davis, MD | |
|
8825 Bee Caves Rd Ste 100, Austin, TX 78746-4721 | |
| (512) 328-3376 | |
| (512) 666-3767 |
| Full Name | Dr Dianne Sherill Davis |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 10 Years |
| Location | 8825 Bee Caves Rd Ste 100, Austin, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114331634 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | S2974 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hopkins Dermatology Apmc | 6709945272 | 4 |
News Archive
Usually, the synthesis of short protein chains (polypeptides) begins with the production of their components, the amino acids.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
Hana Biosciences, Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and nine months ended September 30, 2010, and provided a corporate update.
The U.S. Food and Drug Administration, part of the U.S. Department of Health and Human Services, is requesting a budget of $3.2 billion to protect and promote the public health as part of the President's fiscal year (FY) 2010 budget - a 19 percent increase over the current FDA fiscal year budget.
Merck & Co., Inc., known outside the U.S. and Canada as MSD, today provided further detail on integration plans for the company's research and development, manufacturing and other business operations as part of a global restructuring program announced following the November 2009 merger of Merck and Schering-Plough.
› Verified 9 days ago
| Entity Name | North Dallas Dermatology Associates, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629188065 PECOS PAC ID: 3173588571 Enrollment ID: O20041124000729 |
News Archive
Usually, the synthesis of short protein chains (polypeptides) begins with the production of their components, the amino acids.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
Hana Biosciences, Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and nine months ended September 30, 2010, and provided a corporate update.
The U.S. Food and Drug Administration, part of the U.S. Department of Health and Human Services, is requesting a budget of $3.2 billion to protect and promote the public health as part of the President's fiscal year (FY) 2010 budget - a 19 percent increase over the current FDA fiscal year budget.
Merck & Co., Inc., known outside the U.S. and Canada as MSD, today provided further detail on integration plans for the company's research and development, manufacturing and other business operations as part of a global restructuring program announced following the November 2009 merger of Merck and Schering-Plough.
› Verified 9 days ago
| Entity Name | Hopkins Dermatology Apmc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760075253 PECOS PAC ID: 6709945272 Enrollment ID: O20210602000594 |
News Archive
Usually, the synthesis of short protein chains (polypeptides) begins with the production of their components, the amino acids.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
Hana Biosciences, Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and nine months ended September 30, 2010, and provided a corporate update.
The U.S. Food and Drug Administration, part of the U.S. Department of Health and Human Services, is requesting a budget of $3.2 billion to protect and promote the public health as part of the President's fiscal year (FY) 2010 budget - a 19 percent increase over the current FDA fiscal year budget.
Merck & Co., Inc., known outside the U.S. and Canada as MSD, today provided further detail on integration plans for the company's research and development, manufacturing and other business operations as part of a global restructuring program announced following the November 2009 merger of Merck and Schering-Plough.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dianne Sherill Davis, MD 8825 Bee Caves Rd Ste 100, Austin, TX 78746-4721 Ph: (512) 328-3376 | Dr Dianne Sherill Davis, MD 8825 Bee Caves Rd Ste 100, Austin, TX 78746-4721 Ph: (512) 328-3376 |
News Archive
Usually, the synthesis of short protein chains (polypeptides) begins with the production of their components, the amino acids.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
Hana Biosciences, Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and nine months ended September 30, 2010, and provided a corporate update.
The U.S. Food and Drug Administration, part of the U.S. Department of Health and Human Services, is requesting a budget of $3.2 billion to protect and promote the public health as part of the President's fiscal year (FY) 2010 budget - a 19 percent increase over the current FDA fiscal year budget.
Merck & Co., Inc., known outside the U.S. and Canada as MSD, today provided further detail on integration plans for the company's research and development, manufacturing and other business operations as part of a global restructuring program announced following the November 2009 merger of Merck and Schering-Plough.
› Verified 9 days ago
Dr. John Joseph Ghidoni Iii, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 8229 Shoal Creek Blvd, Suite#101, Austin, TX 78757 Phone: 512-371-7400 Fax: 512-371-7488 | |
Moise Levy, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1301 Barbara Jordan Blvd Ste 200, Austin, TX 78723 Phone: 512-628-1920 Fax: 512-628-1921 | |
Dr. Susan Elizabeth Dozier, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 8240 N Mo Pac Expwy, Suite 355, Austin, TX 78759 Phone: 512-527-9020 Fax: 512-527-9000 | |
Dr. Gregory A. Nikolaidis, Dermatology Medicare: Medicare Enrolled Practice Location: 8825 Bee Cave Rd, Suite 100, Austin, TX 78746 Phone: 512-328-3376 Fax: 512-399-6895 | |
Amy Ayres Mcclung, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9701 Brodie Ln Ste 106, Austin, TX 78748 Phone: 512-280-3939 Fax: 512-280-3938 | |
Stanley Tyler Hollmig, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1601 Trinity St Ste 704b, Austin, TX 78712 Phone: 512-324-7468 Fax: 512-324-7469 | |
Dr. Lauren Piilani Rimoin, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 8825 Bee Caves Rd Ste 100, Austin, TX 78746 Phone: 512-328-3376 Fax: 512-666-3767 |